Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient

• Main Authors: Hong-Juan Dong, Li-Jie Yang, Jian-Hong Wang, Yi Huan, Qing-Xian Bai
• Format: Article
• Language: English
• Published: MDPI AG 2012-09-01
• Series: International Journal of Molecular Sciences
• Subjects: aspergillosis; liver; <em>Aspergillus</em><em> fumigatus</em> caspofungin acetate
• Online Access: http://www.mdpi.com/1422-0067/13/9/11063

Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, <em>Aspergillus</em> infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.